Bet on Earnings, No...
Health Care: Drugs
Puma Biotechnology Inc (PBYI: NYSE)
$38.87 -0.33 | -0.84%
06/18/13 - 04:02 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -74.35M | -10.23M | -15.98K | -16.84K |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | -10.61M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 395.00K | 586.21K | -2.27K | 21.00 |
| (Decrease) Increase In Other Current Liabilities | 20.72M | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Working Capital | 186.00K | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 20.09M | 8.09M | 0.00 | 0.00 |
| Net Cash From Continuing Operations | -44.01M | -1.83M | -18.25K | -16.82K |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -44.01M | -1.83M | -18.25K | -16.82K |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.06M | -253.33K | 0.00 | 0.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -159.00K | -1.49M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.22M | -1.75M | 0.00 | 0.00 |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 129.26M | 56.89M | 16.30K | 19.15K |
| Repayment of Long-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 0.00 | 61.98K | 0.00 | 0.00 |
| Net Cash From Financing Activities | 129.26M | 56.95M | 16.30K | 19.15K |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 84.03M | 53.38M | -1.95K | 2.34K |
Portfolios with PBYI
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
Latest PBYI Headlines from TheStreet
- 4 Stocks Spiking on Big Volume 05.28.13 | 10:05 pm
- 3 Stocks Spiking on Big Volume 04.15.13 | 02:04 pm
- Top Insider Trades: NSH PBYI CONN EPHC 12.12.12 | 09:12 am
- Insiders Trading BLK FIRE SONS PBYI 10.23.12 | 09:10 am
- Insiders Trading NCT, PBYI, NAV, OPK 07.30.12 | 01:07 pm
- Insiders Trading FDO, PBYI, SUMR, ENTG 07.19.12 | 09:07 am
- Top Insider Trades: SPB PBYI GPK AXS 12.31.69 | 07:12 pm
Press Releases for PBYI
- Puma Biotechnology To Present At Cowen Healthcare Conference - Business Wire 02.26.13 | 08:02 am
- Puma Biotechnology Announces Agreement With FDA On Special Protocol Assessment For Phase III Trial Of PB272 (Neratinib) In HER2-Positive Metastatic Breast Cancer Patients - Business Wire 02.20.13 | 08:02 am
- Puma Biotechnology To Present At Leerink Swann Global Healthcare Conference - Business Wire 02.06.13 | 08:02 am
- Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data At CTRC-AACR San Antonio Breast Cancer Symposium - Business Wire 12.07.12 | 06:12 pm
- Puma Biotechnology Reports Third Quarter 2012 Financial Results - Business Wire 11.14.12 | 08:11 am
- Puma Biotechnology To Present At Lazard Healthcare Conference - Business Wire 11.07.12 | 08:11 am
- Puma Biotechnology Closes $138 Million Public Offering Of Common Stock - Business Wire 10.24.12 | 02:10 pm
- Puma Biotechnology Announces Underwriters’ Full Exercise Of Overallotment Option, Increasing Total Offering Size To $138 Million - Business Wire 10.22.12 | 08:10 am
- Puma Biotechnology Announces Upsizing And Pricing Of $120 Million Public Offering Of Common Stock - Business Wire 10.18.12 | 06:10 pm
- Puma Biotechnology To Present At UBS Global Life Sciences Conference - Business Wire 09.12.12 | 08:09 am
Partner Headlines for PBYI
- Analysts: CarMax Can Maintain Momentum and 3 New Opinions Investors Must Take a Peek At - Wall St. Cheat Sheet 04.02.13 | 11:04 am
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
